

1 Cerebral aneurysm walls contain myoglobin that is possibly produced by myofibroblasts and  
2 contributes to wall thickening

3

4 Hidehito Kimura, M.D., Ph.D.<sup>1</sup>; Tatsuya Mori M.D.<sup>1</sup>; Kosuke Hayashi, D.Eng.<sup>2</sup>; Yusuke  
5 Ikeuchi M.D.<sup>1</sup>; Kazuhiro Tanaka M.D. Ph. D.<sup>1</sup>; Masakazu Shinohara M.D. Ph. D.<sup>4,5</sup>; Akio  
6 Tomiyama, D.Eng.<sup>2</sup>; Eiji Kohmura, M.D., Ph.D.<sup>3</sup>; Takashi Sasayama, M.D., Ph.D.<sup>1</sup>

7

8 <sup>1</sup>Department of Neurosurgery, Kobe University Graduate School of Medicine, Kobe, Japan

9 <sup>2</sup>Graduate School of Engineering, Kobe University, Kobe, Japan

10 <sup>3</sup>Department of Neurosurgery, Kinki Central Hospital, Itami, Japan

11 <sup>4</sup>Division of Molecular Epidemiology, Kobe University Graduate School of Medicine, Kobe,  
12 Japan

13 <sup>5</sup>The Integrated Center for Mass Spectrometry, Kobe University Graduate School  
14 of Medicine, Kobe, Japan

15

16 Short title: Cerebral aneurysms have myoglobin in the wall

17

18 Corresponding author:

19 Hidehito Kimura

20 Email address: [hkimura@med.kobe-u.ac.jp](mailto:hkimura@med.kobe-u.ac.jp)

21 Department of Neurosurgery

22 Kobe University Graduate School of Medicine

23 Kusunoki-cho 7-5-1, Chuo-ku, Kobe 650-0017, JAPAN

24 Tel: +81-78-382-5966

25 Fax: +81-78-382-5979

26 Kobe, Japan

27

28 Total word count: 5939

29 Abstract:

30 **Background:** Cerebral aneurysms are associated with subarachnoid hemorrhages if ruptured;

31 however, mechanisms underlying aneurysmal wall thinning and thickening remain unclear.

32 We previously identified patterns of hemodynamic flow in aneurysms that are associated

33 with wall thickening and thinning, and in this study our objective was to uncover the

34 biological basis for these findings.

35 **Methods:** Cerebral aneurysmal wall samples were collected between August 2020 and

36 March 2022 for proteomic analysis and immunohistological investigation of smooth muscle

37 cells, myoglobin, and inducible nitric oxide synthase (iNOS) expression. We examined the

38 co-localization of myoglobin expression within smooth muscle cells, identified by  $\alpha$ -smooth

39 muscle actin ( $\alpha$ -SMA) staining, and myofibroblasts, identified by periostin staining. We

40 measured collagen density in the samples using Sirius Red staining and investigated its

41 correlation with myoglobin density.

42 **Results:** Analysis of proteins extracted from an area of thickening in the aneurysmal wall of

43 one patient confirmed the presence of myoglobin. In 24 formalin-fixed aneurysmal wall

44 samples, 19 expressed myoglobin, with 11 showing strong expression, and eight showing

45 weak expression. Myoglobin was scattered or clustered within the vascular smooth muscle

46 layer and tended to be expressed at sites other than where iNOS was identified. Double-label

47 immunofluorescence staining confirmed that the myoglobin-positive rate within  $\alpha$ -SMA-

48 positive cells and  $\alpha$ -SMA-positive areas was  $33.2\pm 23.8\%$  and  $31.3\pm 37.8\%$ , respectively,

49 whereas within periostin-positive cells and periostin-positive areas it was  $92.2\pm 13.7\%$  and

50  $79.8\pm 29.5$ , respectively. A moderate correlation was observed between the density of

51 myoglobin and collagen in the same sample field, with a Spearman's rank correlation

52 coefficient of 0.593 ( $p = 0.036$ ).

53 **Conclusions:** Cerebral aneurysmal walls express myoglobin, which may be produced by  
54 myofibroblasts in the wall. Areas with high myoglobin levels retain high levels of collagen  
55 fibers, and myoglobin may be involved in wall thickening by suppressing destructive changes  
56 in the extracellular matrix collagen fibers.

57

58 Non-standard Abbreviations and Acronyms:

59  $\alpha$ -SMA,  $\alpha$ -smooth muscle actin

60 CFD, computational fluid dynamics

61 ECM, extracellular matrix

62 iNOS, inducible nitric oxide synthase

63 MMP, macrophage-derived matrix metalloproteinase

64 NO, nitric oxide

65 OSI, oscillatory shear stress

66 ROS, reactive oxygen species

67 SMC, smooth muscle cell

68 WSS, wall shear stress

69 Introduction:

70 Recent advances in imaging technology have increased the frequency (about 1–5% of  
71 the general population) with which unruptured cerebral aneurysms can be identified.<sup>1-3</sup>

72 Cerebral aneurysms can cause subarachnoid hemorrhages if ruptured, which can be fatal.<sup>4</sup>

73 Most unruptured aneurysms are asymptomatic and do not change in shape; however, some  
74 aneurysms are known to rupture after enlargement.<sup>5</sup> It is recommended to identify aneurysms  
75 that display a higher likelihood of rupture and prevent rupture with surgical intervention.<sup>6</sup>

76 Previous studies have predicted the characteristics of aneurysms that are prone to  
77 rupture based on factors such as size, location, shape, and patient background. Although  
78 larger aneurysms are more likely to rupture, small cerebral aneurysms can still rupture.<sup>7-10</sup>  
79 The pathophysiology of aneurysm rupture remains unclear; therefore, it is difficult to predict  
80 the growth or rupture of individual aneurysms.

81 Recent advances in histopathological and molecular biology studies of cerebral  
82 aneurysms have shed light on aneurysmal formation, enlargement, and rupture.<sup>11,12</sup> A  
83 cerebral aneurysm is a localized bulge of a cerebral blood vessel pathologically characterized  
84 by degenerative changes in the wall. Aneurysmal growth is considered to be induced by  
85 mechanical damage to the vascular endothelium from hemodynamic stress on the vessel wall,  
86 that is, increased wall shear stress, which leads to the disappearance of the internal elastic  
87 lamina and degeneration of the smooth muscle tunica media layer. The vulnerable areas  
88 become aneurysms.<sup>13</sup> Vulnerability is believed to be caused by chronic inflammation, mainly  
89 involving macrophages.<sup>14</sup> Activated macrophages and smooth muscle cells (SMCs) produce  
90 macrophage-derived matrix metalloproteinase (MMP)-2, MMP-9, inducible nitric oxide  
91 synthase (iNOS), and reactive oxygen species (ROS), all of which induce extracellular matrix  
92 (ECM) degeneration, and SMC apoptosis, thereby promoting aneurysm formation.<sup>6,13,15</sup> As

93 the ECM in the tunica media degenerates, the tunica media thins, and eventually only the  
94 tunica externa remains.<sup>16</sup>

95 These observations explain why the aneurysmal walls become fragile and thin, and  
96 since aneurysms are believed to rupture at the thinning part of the wall, they clarify the steps  
97 leading to aneurysm rupture.<sup>12</sup> However, this does not explain why thick- and thin-walled  
98 regions coexist within a single aneurysm. Uncovering the precise mechanisms responsible for  
99 the disparity between the thin- and thick-walled regions of the aneurysmal wall is crucial for  
100 elucidating the true mechanism of rupture.

101 We previously performed a computational fluid dynamics (CFD) analysis of cerebral  
102 aneurysms to elucidate the hemodynamic factors that induce wall thinning and thickening.  
103 We found that the degree of blood flow stagnation is related to the degree of wall thinning  
104 and thickening. In other words, we found that the aneurysmal wall is more likely to be  
105 thinned in areas where the wall shear stress vector hardly fluctuates and the blood flow is  
106 unidirectional during one cardiac cycle, whereas the wall is more likely to be thickened in  
107 areas where the wall shear stress vector dramatically fluctuates and the flow direction tends  
108 to change in multiple directions.<sup>17,18</sup> These findings were consistent with another published  
109 report.<sup>19</sup>

110 To elucidate the biological mechanisms by which these hemodynamic differences  
111 induce thickness change of the aneurysmal wall, we performed a proteome analysis to detect  
112 differentially expressed proteins in the thin or thick portions of the aneurysmal wall and  
113 compared protein expression levels and location by immunohistochemistry.

114

115 Methods:

116 Patients

117 This study was conducted in accordance with criteria from the Strengthening the  
118 Reporting of Observational Study in Epidemiology statement and approved by the local  
119 ethics committee of our institution (#B210170).<sup>20</sup> Written informed consent was obtained  
120 from all the patients. Patients who underwent clipping of unruptured cerebral aneurysms at  
121 our hospital between August 2020 and March 2022 were included in this study. The  
122 aneurysms were sampled after clipping to occlude their blood flow. If the aneurysm was  
123 deep-seated or small, then excision of the aneurysmal wall was not performed because of  
124 technical difficulty. The aneurysm was observed under an operating microscope before  
125 clipping; thin-walled areas appeared red, and thickened areas of the wall were uniformly  
126 white or white-yellow. Samples were collected from the wall, as widely separated as possible.  
127 The samples were stored frozen or infiltrated with formalin. A total of 29 specimens were  
128 successfully obtained from 21 patients who underwent aneurysmal clipping. There were 10  
129 men and 11 women, and their mean age was  $65.5 \pm 13.1$  years. There were 10 middle cerebral  
130 artery, six anterior cerebral artery, and five internal cerebral artery aneurysms; 16 aneurysms  
131 were unruptured and five had ruptured. Mean aneurysm size was 6.68 mm (range: 4.5–10.1  
132 mm).

133 A total of 11 frozen specimens of arterial wall (four thickened, seven thinned) were  
134 obtained from nine out of 12 patients, including two patients from whom samples from both  
135 thinned and thickened areas of the wall were obtained. Samples were not collected from the  
136 remaining three patients because of technical difficulties. Proteome analysis was performed  
137 on these 11 specimens. A further 24 formalin-fixed samples (10 thickened, six thinned, and  
138 eight mixed-wall regions) were collected from 17 patients for immunohistochemical analysis  
139 (Suppl Fig. 1).

140 Proteome analysis

141 (1) Protein extraction: The required volume of lysis buffer was prepared according to the  
142 procedure of the protein extraction kit (Nuclear Extract Kit; Active Motif, Carlsbad, CA,  
143 USA), the sample was added, and tissue disruption was performed using a sonicator.

144 The amount of protein in the extract was measured using a protein quantification reagent  
145 (Pierce BCA Protein Assay Kit; Thermo Fisher Scientific, Waltham, MA, USA), and the  
146 samples were prepared for electrophoresis.

147 (2) Protein electrophoresis and staining: Samples were electrophoresed on sodium dodecyl-  
148 sulphate (SDS)-polyacrylamide gels. Silver staining was performed after electrophoresis  
149 using a silver staining kit (ProteoSilver Plus Silver Stain Kit; Sigma-Aldrich) according to the  
150 kit instructions.

151 (3) Liquid chromatography-tandem mass spectrometry (LC-MS/MS). Silver-stained protein  
152 bands that were specifically observed in either the thickened or thinned aneurysmal wall  
153 areas were identified and excised. LC-MS/MS analysis was performed using an LCMS-IT-  
154 TOF instrument (Shimadzu, Kyoto, Japan) interfaced with a nanoreverse-phase liquid  
155 chromatography system (Shimadzu). MS/MS data were analyzed using Mascot (version  
156 2.3.01; Matrix Science, London, UK), as previously reported.<sup>21</sup> The search parameters were  
157 as follows: enzyme, trypsin; variable modifications, carbamidomethyl (Cys), deamidated  
158 (Asn, Gln), and oxidation (Met); peptide mass tolerance,  $\pm 50$  ppm; fragment mass tolerance,  
159  $\pm 0.05$  Da; and max missed cleavages.<sup>21</sup>

160 Western blot analysis

161 Western blotting was performed to confirm the myoglobin expression. We used the  
162 following antibody: anti-myoglobin (diluted 1:500, SC-74525; Santa Cruz Biotechnology,  
163 Dallas, TX, USA).

164 Immunohistological analysis



165 Immunohistochemical analysis was performed to detect myoglobin expression in the  
166 aneurysmal wall, to observe the characteristics of the expression site and localization, and the  
167 relationship between SMCs and iNOS expression. The specimens were fixed in 4%  
168 formaldehyde and embedded in paraffin. The samples were originally 2–3 mm in size, and 2-  
169  $\mu\text{m}$ -thick axial slices were prepared. The sections were deparaffinized and immersed in  
170 methanol containing 3% hydrogen peroxide. Antigen retrieval was performed by heat  
171 mediation in a 0.01 mol/L citrate buffer (pH 6.0) for 15 min by autoclaving (121 °C, 2 atm).  
172 The sections were then incubated with primary antibodies against  $\alpha$ -smooth muscle actin ( $\alpha$ -  
173 SMA; diluted 1: 100, ab5694; Abcam, Cambridge, UK), myoglobin (diluted 1: 500, SC-  
174 74525, Santa Cruz Biotechnology, Dallas, TX), and iNOS (diluted 1:1000, 18985-1-AP,  
175 Proteintech group, Manchester, UK) at 4 °C overnight. The sections were allowed to react  
176 with a peroxidase-conjugated anti-rabbit IgG polyclonal antibody or anti-mouse IgG  
177 polyclonal antibody (Histofine Simple Stain MAX-PO; Nichirei, Tokyo, Japan) for 60 min,  
178 and the reaction products were visualized by immersing the sections in 0.03%  
179 diaminobenzidine solution containing 2 mM hydrogen peroxide for 1–5 min.

180 Double-label immunofluorescence staining was used to investigate the origin of  
181 myoglobin in aneurysmal walls.  $\alpha$ -SMA-positive cells have been reported to include SMCs  
182 and myofibroblasts, which are also known to have myoglobin. Therefore, we searched for the  
183 presence of myofibroblasts in the specimens.<sup>22-24</sup> Periostin was selected as a biomarker of  
184 myofibroblasts.<sup>22,25,26</sup> Staining was performed using the ImmPRESS Duet Double Staining  
185 Polymer Kit (Vector Laboratories, Burlingame, CA, USA). The sections were incubated with  
186 mouse primary antibodies against  $\alpha$ -SMA (dilution 1:100, ab5694, Abcam, United Kingdom),  
187 myoglobin (diluted 1:500, SC-74525, Santa Cruz Biotechnology, Dallas, TX, USA), and  
188 rabbit primary antibodies against periostin (dilution 1:400, Proteintech, 19899-1-AP) for 1 h  
189 at room temperature.

190 The sections were then incubated with VectorFluor Duet Reagent for 30 min.  
191 Coverslips were mounted using ProLong™ Gold Antifade Reagent with DAPI (Life  
192 Technologies). The images were acquired using a Keyence BZ-X700 fluorescence  
193 microscope. The numbers of immunopositive cells and immunopositive areas were measured  
194 in the entire field of the photographs. The results are presented as the average value for each  
195 patient (cells/field). The colocalization ratio was calculated and represented as a percentage  
196 using a BZ-X analyzer.

197 In addition, Sirius Red staining was performed to quantify the density of collagen.  
198 Uniformly concentrated areas on the Sirius Red-stained photomicrograph were randomly  
199 selected (200–300  $\mu\text{m}^2$ ), and the same areas of the fluorescent myoglobin-stained  
200 photomicrographs were marked. The percentages of collagen- and myoglobin-containing  
201 areas in the selected fields were quantified using image analysis software (Image J 1.48v,  
202 National Institutes of Health), and correlations were examined.<sup>27</sup>

203

#### 204 Statistical analysis

205 All continuous quantitative data were represented as means  $\pm$  standard deviation (SD)  
206 and categorical variables as percentages. The Mann–Whitney U test was used to evaluate the  
207 co-localization rate of myoglobin with  $\alpha$ -SMA and periostin, and periostin with  $\alpha$ -SMA.  
208 Spearman’s rank correlation test was performed to examine potential correlations between  
209 the Sirius red-positive areas and myoglobin-positive areas. The degree of association was  
210 interpreted as follows: strong (absolute value of correlation coefficient,  $|r| = 0.7–1$ ), moderate  
211 ( $|r| = 0.5–0.7$ ), or low ( $|r| = 0.3–0.5$ ).

212 All statistical analyses were performed using EZR (Saitama Medical Center, Jichi  
213 Medical University, Saitama, Japan), which is a graphical user interface for R 3.4.3 (R

214 Foundation for Statistical Computing, Vienna, Austria). A two-sided  $p < 0.05$  was considered  
215 statistically significant.

216

217 Results

218 Detection of myoglobin

219 Silver staining was performed on the protein electrophoresis gels of samples from 11  
220 aneurysmal wall sites (four thickened and seven thinned walls), including two thin and thick  
221 paired regions. In one of the two patients with samples from both thinned and thickened wall  
222 regions, we observed a prominent band that appeared only in the sample from the thickened  
223 area of the wall (Fig. 1). The equivalent band was faint in the protein electrophoresis gel from  
224 the second patient with both thick and thin wall areas, and was not clearly seen in samples  
225 from the remaining two thickened sites. Hence, this band was detected intensely in one of the  
226 four samples from the thickened areas. This band was extracted and subjected to proteomic  
227 analysis, which identified it as human myoglobin protein.

228 Western blot analysis confirmed the presence of myoglobin in the thickened walls (Fig. 1).

229

230 Location and distribution of myoglobin in the aneurysmal wall

231 Among the 24 formalin-fixed samples (10 thickened, six thinned, and eight mixed-  
232 wall regions), 19 expressed myoglobin, with strong expression in 11 and weak expression in  
233 remaining eight. For the six specimens from thinned wall regions, two had faint myoglobin  
234 expression, and the remaining four showed no expression. SMC and iNOS were found in all  
235 the samples. Regarding the distribution of myoglobin, some areas were scattered and  
236 dispersed within the SMC layer of the wall, while others were relatively clustered in the  
237 vicinity of the SMC layer (Fig. 2).

238 In contrast, iNOS-expressing regions were generally more sparse and with coarse  
239 staining, and myoglobin expression was less likely to occur in these regions. On the other  
240 hand, myoglobin-expressing regions were relatively densely packed within the SMC layers.

241

242 Origin of myoglobin

243 Double-fluorescence immunohistological examination revealed scattered myoglobin  
244 in the regions containing  $\alpha$ -SMA, but also in other areas without  $\alpha$ -SMA (Fig. 3). The co-  
245 localization rate of myoglobin within  $\alpha$ -SMA positive cells was  $33.2\pm 23.8\%$ , and  
246  $31.3\pm 37.8\%$  in the  $\alpha$ -SMA-containing area. On the other hand, the co-localization rate of  
247 myoglobin within periostin-positive cells was  $92.2\pm 13.7\%$ , and  $79.8\pm 29.5$  in the periostin-  
248 containing area; the distribution of periostin and myoglobin was almost identical (Fig. 3).

249 The difference of co-localization ratios of myoglobin within  $\alpha$ -SMA-positive cells  
250 and within periostin-positive cells (Fig. 3C, upper panel) was statistically significant  
251 ( $p < 0.001$ ) and difference of co-localization ratios of myoglobin within  $\alpha$ -SMA-positive areas  
252 and within periostin-positive areas (Fig. 3C, lower panel) was also statistically significant  
253 ( $p < 0.001$ ). Receiver operating characteristic curve analysis showed that there were no  
254 significant difference between comparison of within-cell co-localization (myoglobin/periostin,  
255 vs myoglobin/ $\alpha$ -SMA, solid line in Suppl Fig. 2; area under the curve (AUC)  $0.975$  [95% CI  
256  $0.937 - 1$ ]) and area co-localization (myoglobin/periostin vs myoglobin/ $\alpha$ -SMA, dashed line  
257 in Suppl Fig. 2; AUC  $0.867$  [95% CI  $0.734 - 0.999$ ]),  $p = 0.0525$ .

258 After the double staining of  $\alpha$ -SMA and periostin, the co-localization rate of periostin  
259 within  $\alpha$ -SMA-positive areas was  $41.8\pm 24.3\%$ , and  $57.5\pm 24.8\%$  in the  $\alpha$ -SMA-positive cells  
260 (Fig. 4).

261

262 Relationship between myoglobin density and collagen fiber density

263           On a photomicrograph of a Sirius Red-stained section of an aneurysm wall, a uniform  
264 area of tissue was selected for measurement of collagen density. The same area of tissue  
265 section was evaluated for myoglobin density on a photomicrograph of a myoglobin-stained  
266 section. Fourteen areas from 12 samples were compared. A moderate correlation was  
267 observed, with a Spearman's rank correlation coefficient of 0.593 ( $p = 0.036$ ) (Fig. 5).

268

## 269 Discussion

270           To the best of our knowledge, this is the first report of myoglobin detection in the  
271 human cerebral aneurysmal wall. Furthermore, we identified periostin as a potential indicator  
272 of myofibroblasts within the aneurysmal wall where myoglobin is present.

273           Here, we discuss the characteristics, possible origin, and role of myoglobin in  
274 aneurysmal walls.

275

## 276 Characteristics of myoglobin expression in the aneurysmal wall

277           Myoglobin is a well-known cytoplasmic heme protein that is found in cardiac and  
278 skeletal muscle cells as an oxygen storage protein. Myoglobin is present in vascular smooth  
279 muscle, however, no reports have shown that myoglobin is expressed in cerebral aneurysm  
280 walls.<sup>28</sup> In this study, myoglobin was mostly observed in the thickened areas of the  
281 aneurysmal wall, and less abundantly in the thinned areas. Myoglobin localization differed  
282 from that of iNOS, which was more frequently expressed in areas with scarce myoglobin (Fig.  
283 2).

284           Myoglobin was found to be scattered between and inside SMCs in some areas of the  
285 tunica media, and clustered in the vicinity of the SMC layer in other areas (Fig. 1 C, D, Fig.  
286 2). Myoglobin was commonly located between the smooth muscle layer and regions that

287 exhibited elevated iNOS expression, suggesting its presence acted as a barrier to iNOS  
288 infiltration (Fig. 1 D).

289

290 Origin of myoglobin in aneurysms

291 Myoglobin is reported to be expressed in the vascular SMC layer; therefore, we  
292 initially assumed that myoglobin in the aneurysmal wall was derived from vascular smooth  
293 muscle cells.<sup>29</sup> Consequently, we performed double staining for  $\alpha$ -SMA and myoglobin, but  
294 found that the expression sites only partially overlapped; the myoglobin-positive rate within  
295  $\alpha$ -SMA-positive cells was  $33.2\pm 23.8\%$ , and within  $\alpha$ -SMA-positive areas was  $31.3\pm 37.8\%$ .  
296 This means only approximately 30% of the  $\alpha$ -SMA-positive cells showed expression of  
297 myoglobin, and approximately 70% did not.

298  $\alpha$ -SMA-positive cells are known to include vascular smooth muscle and  
299 myofibroblasts.<sup>22</sup> In addition, myofibroblasts have been recently reported to produce  
300 myoglobin.<sup>25,26</sup>

301 We hypothesized that myofibroblasts exist in the aneurysmal wall and produce  
302 myoglobin. Hence, we performed immunofluorescence staining using periostin, a specific  
303 marker for myofibroblasts.<sup>22,25,26</sup> Periostin expression was confirmed in all thickened areas of  
304 the aneurysmal wall. The myoglobin-positive rates within the periostin-positive cells and  
305 periostin-positive areas were  $92.2\pm 13.7\%$  and  $79.8\pm 29.5$ , respectively, indicating that  
306 myoglobin was expressed in about 80–90% of the periostin-positive cells and areas. This  
307 demonstrates that myofibroblasts certainly exist in the aneurysmal wall and that many of  
308 them express myoglobin.

309 As regards the accuracy of differentiating myoglobin-positive rates in periostin-  
310 positive cells and areas compared with SMA-positive cells and areas, the cell count co-

311 localization approach demonstrated marginally better accuracy, however the difference was  
312 not statistically significant ( $p = 0.0525$  Suppl Fig. 2).

313 Furthermore, the periostin-positive rates within all  $\alpha$ -SMA-positive areas and  $\alpha$ -SMA-  
314 positive cells were  $41.8 \pm 24.3\%$  and  $57.5 \pm 24.8\%$ , respectively, suggesting that about half of  
315 the cells previously thought to be vascular smooth muscle may have been myofibroblasts.

316

317 Significance of myoglobin in the aneurysmal wall

318 Myoglobin has been reported to function as a scavenger of NO and ROS.<sup>30,31</sup> NO is  
319 produced by iNOS within inflammatory cells, generates toxic proteins that impair the  
320 function of cytoskeletal proteins involved in ECM remodeling, and causes aneurysmal  
321 development.<sup>32,33</sup> ROS are produced by macrophages, are major mediators of various  
322 inflammatory cascades, and are known to promote aneurysmal development as well.<sup>12,34</sup>  
323 These macrophage-derived proteinases promote the degradation of the ECM and decrease  
324 collagen production at the aneurysmal wall, leading to thinning of the media and subsequent  
325 weakening/rupture.<sup>35</sup>

326 In this study, we found that the density of myoglobin in the cerebral aneurysmal walls  
327 correlated with the density of collagen fibers. Myoglobin is suggested to inactivate these  
328 macrophage-derived proteinases and suppress the degradation of the ECM, particularly  
329 collagen, in the aneurysmal wall. The myoglobin found in the aneurysmal walls in this study  
330 was found mostly in the thickened areas and less in the thinned areas, suggesting that  
331 myoglobin may prevent wall thinning. Figure 6 presents a potential biological role of  
332 myoglobin in aneurysmal walls.

333 Hemodynamic research has demonstrated that biological changes in the aneurysmal  
334 wall are triggered by hemodynamic stress on the wall.<sup>19,36,37</sup> In areas exposed to high wall  
335 shear stress (WSS), WSS vectors are less variable, oscillatory shear index (OSI) is low, and

336 MMP-2 and MMP-9 are activated via NO and ROS derived from vascular endothelial cells  
337 and macrophages, resulting in ECM degradation, thinning of the media, and apoptosis of  
338 SMCs and fibroblasts.<sup>36,37</sup> In contrast, areas with low WSS are areas of relative stagnation of  
339 blood flow where OSI is high and inflammatory cell infiltration causes wall thickening  
340 changes.<sup>19,37</sup> The detailed mechanisms of wall thickening are still unknown; however,  
341 myoglobin, which was discovered in the thickened areas, may counteract wall-destructive  
342 substances such as MMP-2 and MMP-9 by scavenging NO and ROS, resulting in the wall  
343 thickening.

344 Meng et al. reported that SMCs migrate during aneurysmal wall enlargement. In this  
345 study, we demonstrated that at least half of the cells in the aneurysmal wall that were thought  
346 to be SMCs were possibly myofibroblasts, which are also  $\alpha$ -SMA-positive.<sup>37</sup> Myofibroblasts  
347 differentiate from fibroblasts, and it has also been reported that fibroblasts do not become  $\alpha$ -  
348 SMA positive.<sup>22,38</sup> Fibroblasts are reported to originally reside in the adventitia of the arterial  
349 wall.<sup>39,40</sup> In the aneurysmal growth stage, the area where the wall shear stress vector  
350 fluctuates significantly during one cardiac cycle is considered to be the area where blood  
351 flow is relatively stagnant. This hemodynamic condition may allow fibroblasts in the  
352 adventitia to differentiate into myofibroblasts and produce myoglobin, which may prevent  
353 wall weakening and induce wall thickening (Fig. 6).

354

#### 355 Limitations

356 This study had some limitations. First, the sample size is small. Second, the molecular  
357 biological mechanisms related to wall thickening and thinning are likely to involve numerous  
358 complex factors, and this study only examined pre- and post-processes involving myoglobin.  
359 Third, this study was based only on the histopathological findings. Further investigation is



360 required to clarify the role of myoglobin in aneurysmal walls, including its association with  
361 other mediators of wall thickening and thinning.

362

### 363 Conclusion

364 This is the first study to detect myoglobin in cerebral aneurysmal walls and suggest  
365 that myoglobin is derived from myofibroblasts in the aneurysmal wall. We also found  
366 evidence that myoglobin may be involved in preventing aneurysmal wall thinning by  
367 scavenging iNOS and ROS. Further elucidation of this pathology may lead to a better  
368 understanding of the mechanisms of aneurysmal thinning and thickening. Aneurysms are  
369 believed to rupture at the thinning part of the wall. Understanding the process of wall  
370 thinning may lead to new treatment approaches for unruptured cerebral aneurysms.

371

### 372 Acknowledgements

373 We would like to thank Ms. Tatsuko Uno for assisting with the pathophysiological  
374 analysis and Editage ([www.editage.com](http://www.editage.com)) for English language editing.

375

376

### 377 Sources of Funding

378 This study was supported by JSPS KAKENHI (grant number: JP 22K09232).

379

### 380 Disclosures

381 None.

382 References

- 383 1. Vlak MHM, Algra A, Brandenburg R, Rinkel GJE. Prevalence of unruptured  
384 intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time  
385 period: A systematic review and meta-analysis. *Lancet Neurol.* 2011;10:626–636. doi:  
386 10.1016/S1474-4422(11)70109-0
- 387 2. Silva MA, Chen S, Starke RM. Unruptured cerebral aneurysm risk stratification:  
388 Background, current research, and future directions in aneurysm assessment. *Surg.*  
389 *Neurol. Int.* 2022;13:182. doi: 10.25259/SNI\_1112\_2021
- 390 3. Wermer MJH, Van Der Schaaf IC, Algra A, Rinkel GJE. Risk of rupture of unruptured  
391 intracranial aneurysms in relation to patient and aneurysm characteristics: an updated  
392 meta-analysis. *Stroke.* 2007;38:1404–1410. doi:  
393 10.1161/01.STR.0000260955.51401.cd
- 394 4. Johnston SC, Selvin S, Gress DR. The burden, trends, and demographics of mortality  
395 from subarachnoid hemorrhage. *Neurology.* 1998;50:1413–1418. doi:  
396 10.1212/wnl.50.5.1413
- 397 5. Yonekura M. Small Unruptured Aneurysm Verification (SUAVe Study, Japan):  
398 Interim Report. *Neurol. Med. Chir. (Tokyo).* 2004;44:213–214. doi:  
399 10.2176/nmc.44.21
- 400 6. Kataoka H K. Molecular mechanisms of the formation and progression of intracranial  
401 aneurysms. *Neurol. Med. Chir. (Tokyo).* 2015;55:214–229. doi: 10.2176/nmc.ra.2014-
- 402 7. UCAS Japan Investigators. The Natural Course of Unruptured Cerebral Aneurysms in  
403 a Japanese Cohort. *N. Engl. J. Med.* 2012;366:2474–2482. doi:  
404 10.1056/NEJMoa1113260
- 405 8. Wiebers DO. Unruptured intracranial aneurysms: Natural natural history, clinical  
406 outcome, and risks of surgical and endovascular treatment. *Lancet.* 2003;362:103–110.

- 407           doi: 10.1016/s0140-6736(03)13860-3
- 408    9.    Sonobe M, Yamazaki T, Yonekura M, Kikuchi H. Small Unruptured Intracranial  
409           Aneurysm Verification Study SUAVE Study, Japan. *Stroke*. 2010;41:1969–1977. doi:  
410           10.1161/STROKEAHA.110.585059
- 411    10.   Ikawa F, Morita A, Tominari S, Nakayama T, Shiokawa Y, Date I, et al. Rupture risk  
412           of small unruptured cerebral aneurysms. *J Neurosurg*. 2020;132:69-78. doi:  
413           10.3171/2018.9.JNS181736132.
- 414    11.   Kataoka H. Intracranial Aneurysm Rupture Mechanisms and Prevention. *Jpn J*  
415           *Neurosurg (Tokyo)*. 2013;22:778-785.
- 416    12.   Kataoka H. Molecular mechanisms of the formation and progression of intracranial  
417           aneurysms. *Neurol. Med. Chir. (Tokyo)*. 2015;55:214–229. doi: 10.2176/nmc.ra.2014-  
418           0337
- 419    13.   Sheinberg DL, Mccarthy DJ, Elwardany O, Bryant JP, Luther E, Chen SH, et al.  
420           Endothelial dysfunction in cerebral aneurysms. *Neurosurg. Focus*. 2019;47:E3. doi:  
421           10.3171/2019.4.FOCUS19221
- 422    14.   Tulamo R, Frösen J, Hernesniemi J, Niemelä M. Inflammatory changes in the  
423           aneurysm wall: A review. *J. Neurointerv. Surg*. 2018;10:i58–i67.
- 424    15.   Sunderland K, Jiang J, Zhao F. Disturbed flow’s impact on cellular changes indicative  
425           of vascular aneurysm initiation, expansion, and rupture: A pathological and  
426           methodological review. *J. Cell. Physiol*. 2022;237:278–300. doi: 10.1002/jcp.30569
- 427    16.   Kondo S, Hashimoto N, Kikuchi H, Hazama F, Nagata I, Kataoka H. Apoptosis of  
428           medial smooth muscle cells in the development of saccular cerebral aneurysms in rats.  
429           *Stroke*. 1998;29:181–189. doi: 10.1161/01.str.29.1.181
- 430    17.   Kimura H, Taniguchi M, Hayashi K, Fujimoto Y, Fujita Y, Sasayama T, et al. Clear  
431           Detection of Thin-Walled Regions in Unruptured Cerebral Aneurysms by Using

- 432 Computational Fluid Dynamics. *World Neurosurg.* 2019;121:e287-e295. doi:  
433 10.1016/j.wneu.2018.09.098
- 434 18. Kimura H, Osaki S, Hayashi K, Taniguchi M, Fujita Y, Seta T, et al. Newly Identified  
435 Hemodynamic Parameter to Predict Thin-Walled Regions of Unruptured Cerebral  
436 Aneurysms Using Computational Fluid Dynamics Analysis. *World Neurosurg.*  
437 2021;152:e377–e386. doi: 10.1016/j.wneu.2021.05.107
- 438 19. Soldozy S, Norat P, Elsarrag M, Chatrath A, Costello JS, Sokolowski JD, et al. The  
439 biophysical role of hemodynamics in the pathogenesis of cerebral aneurysm formation  
440 and rupture. *Neurosurg. Focus.* 2019;47:E11. doi: 10.3171/2019.4.FOCUS19232
- 441 20. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The  
442 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)  
443 statement: guidelines for reporting observational studies. *Lancet.* 2007;370:1453–1457.  
444 doi: 10.1016/S0140-6736(07)61602-X
- 445 21. Sekiya R, Nagano T, Moriyama T, Kishi T, Shinke H, Yano E, et al. Occupational  
446 respiratory allergy to lettuce in lettuce farmers. *Clin. Exp. Allergy.* 2020;50:932–941.  
447 doi: 10.1111/cea.13682
- 448 22. Tarbit E, Singh I, Peart JN, Rose’Meyer RB. Biomarkers for the identification of  
449 cardiac fibroblast and myofibroblast cells. *Heart Fail. Rev.* 2019;24:1-15. doi:  
450 10.1007/s10741-018-9720-1
- 451 23. Tasli F, Vardar E, Argon A, Kabat T, Deniz S, Nart A, et al. Histochemical and  
452 immunohistochemical characteristics of elastofibromas. *Pol. J. Pathol.* 2014;65:120–  
453 124. doi: 10.5114/pjp.2014.43961
- 454 24. Forsman M, Pääkkönen V, Tjäderhane L, Vuoristo J, Kallioinen L, Salo T, et al. The  
455 Expression of Myoglobin and ROR2 Protein in Dupuytren’s Disease. *J. Surg. Res.*  
456 2008;146:271–275. doi: 10.1016/j.jss.2007.06.022

- 457 25. Lv H, Liu R, Fu J, Yang Q, Shi J, Chen P, et al. Epithelial cell-derived periostin  
458 functions as a tumor suppressor in gastric cancer through stabilizing p53 and E-  
459 cadherin proteins via the Rb/ E2F1/p14ARF/Mdm2 signaling pathway. *Cell Cycle*.  
460 2014;13:2962–2974. doi: 10.4161/15384101.2014.947203
- 461 26. Yuan Q, Cao S, Dong Q, Wang Z, Xu Y, Han Q, et al. ALDH2 Activation Inhibited  
462 Cardiac Fibroblast-to-Myofibroblast Transformation Via the TGF- $\beta$ 1/Smad Signaling  
463 Pathway. *J. Cardiovasc. Pharmacol.* 2019;73:248–256. doi:  
464 10.1097/FJC.0000000000000655
- 465 27. Hayashi T, Yamamoto S, Hamashima T, Mori H, Sasahara M, Kuroda S. Critical role  
466 of platelet-derived growth factor- $\alpha$  in angiogenesis after indirect bypass in a murine  
467 moyamoya disease model. *J. Neurosurg.* 2020;134:1535–1543. doi:  
468 10.3171/2020.3.JNS193273
- 469 28. Meng H, Tutino VM, Xiang J, Siddiqui A. High WSS or low WSS? Complex  
470 interactions of hemodynamics with intracranial aneurysm initiation, growth, and  
471 rupture: toward a unifying hypothesis. *AJNR. Am. J. Neuroradiol.* 2014;35:1254–62.  
472 doi: 10.3174/ajnr.A3558
- 473 29. Qiu Y, Sutton L, Riggs AF. Identification of Myoglobin in Human Smooth Muscle. *J.*  
474 *Biol. Chem.* 1998;273:23462–32. doi: 10.1074/jbc.273.36.23426
- 475 30. Ordway GA, Garry DJ. Myoglobin: An essential hemoprotein in striated muscle. *J.*  
476 *Exp. Biol.* 2004;207:3441–3446. doi: 10.1242/jeb.01172
- 477 31. Floege U, Goetze A, and Schrader J. Myoglobin is important for postischemic  
478 recovery in the heart. *Circulation.* 2001;104:II–227
- 479 32. Johanning JM, Franklin DP, Han DC, Carey DJ, Elmore JR. Inhibition of inducible  
480 nitric oxide synthase limits nitric oxide production and experimental aneurysm  
481 expansion. *J. Vasc. Surg.* 2001;33:579–86. doi: 10.1067/mva.2001.111805

- 482 33. Fukuda S, Hashimoto N, Naritomi H, Nagata I, Nozaki K, Kondo S, et al. Prevention  
483 of rat cerebral aneurysm formation by inhibition of nitric oxide synthase. *Circulation*.  
484 2000;101:2532–2538. doi: 10.1161/01.cir.101.21.2532
- 485 34. Aoki T, Nishimura M, Kataoka H, Ishibashi R, Nozaki K, Hashimoto N. Reactive  
486 oxygen species modulate growth of cerebral aneurysms: A study using the free radical  
487 scavenger edaravone and p47phox <sup>-/-</sup> mice. *Lab. Investig.* 2009;89:730–741. doi:  
488 10.1038/labinvest.2009.36
- 489 35. Starke RM, Chalouhi N, Ding D, Raper DMS, Mckisic MS, Owens GK, et al. Vascular  
490 Smooth Muscle Cells in Cerebral Aneurysm Pathogenesis. *Transl. Stroke Res.*  
491 2014;5:338–346. doi: 10.1007/s12975-013-0290-1
- 492 36. Mandelbaum M, Kolega J, Dolan JM, Siddiqui AH, Meng H. A Critical Role for  
493 Proinflammatory Behavior of Smooth Muscle Cells in Hemodynamic Initiation of  
494 Intracranial Aneurysm. *PLoS One*. 2013;8:e74357. doi: 10.1371/journal.pone.0074357
- 495 37. Meng H, Tutino VM, Xiang J, Siddiqui A. High WSS or Low WSS? Complex  
496 Interactions of Hemodynamics with Intracranial Aneurysm Initiation, Growth, and  
497 Rupture: Toward a Unifying Hypothesis. *AJNR Am. J. Neuroradiol.* 2014;35:1254–62.  
498 doi: 10.3174/ajnr.A3558
- 499 38. Tai Y, Woods EL, Dally J, Kong D, Steadman R, Moseley R, et al. Myofibroblasts:  
500 Function, Formation, and Scope of Molecular Therapies for Skin Fibrosis.  
501 *Biomolecules*. 2021;11:1905. doi: 10.3390/biom11081095
- 502 39. Wang H Di, Rätsep MT, Chapman A, Boyd R. Adventitial fibroblasts in vascular  
503 structure and function: the role of oxidative stress and beyond. *Can. J. Physiol.*  
504 *Pharmacol.* 2010;88:177–186. doi: 10.1139/Y10-015
- 505 40. Mackay CDA, Jadli AS, Fedak PWM, Patel VB. Adventitial Fibroblasts in Aortic  
506 Aneurysm: Unraveling Pathogenic Contributions to Vascular Disease. *Diagnostics*

507 (Basel). 2022;12:871. doi: 10.3390/diagnostics12040871

508

509 Figure legends:

510 Figure 1. Detection of human myoglobin protein and its expression in the aneurysmal wall

511 A. Silver-stained sodium dodecyl sulphate-polyacrylamide gel electrophoresis of proteins

512 extracted from thinned and thickened aneurysmal walls. A prominent band was detected in

513 the sample from the thickened wall area (arrowhead). M: molecular weight marker. B.

514 Western blot analysis of the excised band using a primary antibody against myoglobin. C.

515 Aneurysmal wall (H&E, and myoglobin immunohistochemical staining). Myoglobin was

516 found scattered (arrowheads) in the media, or clumped in other areas (encircled). D.

517 Immunohistological examination (upper: double staining for myoglobin (pink) and  $\alpha$ -SMA

518 (brown); lower: single staining for iNOS) revealed that myoglobin was expressed inside

519 (encircled by the black line in the upper photograph) and surrounding the iNOS expression

520 area (encircled by the yellow line in the lower photograph), and  $\alpha$ -SMA-positive vascular

521 smooth muscle was present outside this site (encircled by the black dotted line in the upper

522 photograph).

523  $\alpha$ -SMA:  $\alpha$ -smooth muscle actin; H&E: hematoxylin and eosin; iNOS: inducible nitric oxide

524 synthase

525

526 Figure 2. Expression of  $\alpha$ -SMA, myoglobin and iNOS in the aneurysmal wall

527 Photomicrographs of immunohistochemistry using primary antibodies against  $\alpha$ -SMA (alpha-

528 smooth muscle actin; left), myoglobin (middle), or iNOS (inducible nitric oxide synthase;

529 right) in a representative case with strong and weak expression of myoglobin (A–C, D–F;

530 respectively). Myoglobin was found scattered (encircled in B, E; arrowhead in the inset,

531 magnified view of the encircled area in E) throughout the smooth muscle cell cluster (defined

532 by the presence of  $\alpha$ -SMA, encircled in A, D), but also clumped in other areas (arrow in E).



533 iNOS tended to be expressed at the sites where  $\alpha$ -SMA was not (encircled areas in C, F).

534 Scale bar = 100  $\mu$ m

535

536

537 Figure 3. Expression of myoglobin in  $\alpha$ -SMA- and periostin-positive cells and areas

538 Photomicrographs of double immunofluorescence using primary antibodies against  $\alpha$ -SMA

539 ( $\alpha$ -smooth muscle actin; A, left) and myoglobin (A, middle) and the merged image (A,

540 right) in a section from an aneurysm, and periostin (B, left) myoglobin (B, middle) and the

541 merged image (B, right) in a section from another aneurysm. The main distribution of  $\alpha$ -

542 SMA-positive cells (encircled in A left) is inconsistent with the distribution of myoglobin-

543 positive cell clusters (encircled in A middle). Cells showing weak myoglobin staining were

544 scattered in the smooth muscle layer (dotted circles in A middle). The merged image of  $\alpha$ -

545 SMA and myoglobin (A right) showed that some  $\alpha$ -SMA-positive cells expressed myoglobin

546 (white arrowheads as representative, A right), but others did not (yellow arrowheads as

547 representative, A right). In contrast, the distribution of periostin-positive cells (encircled in B

548 left) was almost consistent with the distribution of myoglobin (encircled in B middle). The

549 merged image demonstrates that almost all periostin-positive cells also expressed myoglobin

550 (arrowheads as representative, B right).

551 The difference of co-localization ratio of myoglobin within  $\alpha$ -SMA-positive cells and within

552 periostin-positive cells (C, upper) was statistically significant (\*\*\*)  $p < 0.001$  and the

553 difference of co-localization ratio of myoglobin within  $\alpha$ -SMA-positive areas and within

554 periostin-positive areas (C, lower) was also statistically significant (\*\*\*  $p < 0.001$ ).

555 Scale bar = 100  $\mu$ m

556

557

558 Figure 4. Relationship of  $\alpha$ -SMA, periostin and myoglobin in the aneurysmal wall.  
559 Photomicrographs of double immunofluorescence using primary antibodies against (A)  $\alpha$ -  
560 SMA (alpha-smooth muscle actin), periostin (B), with merged image of  $\alpha$ -SMA and periostin  
561 (C), and myoglobin (D) (The sections are from the same patient as in Figure 2 lower row.)  
562 The  $\alpha$ -SMA-positive cell clusters (delineated by the white line in A) are partially overlapped  
563 with the periostin-positive cells (delineated by white line in B). In contrast, outside of  $\alpha$ -  
564 SMA-positive cell clusters, other periostin-positive cells were also found (delineated by  
565 dotted line in B). The merged image of  $\alpha$ -SMA and periostin (C) showed that some  $\alpha$ -SMA  
566 positive-cells expressed periostin (white arrowheads as representative), but others did not or  
567 had very weak expression (yellow arrowheads as representative). Myoglobin-positive cells  
568 (D) were expressed in areas consistent with periostin-positive cells, delineated both with solid  
569 and dotted line, and corresponding areas in B, including strong periostin-positive cluster  
570 areas (arrow), as seen in B, C and Figure 2 E. The co-localization rate of periostin within  $\alpha$ -  
571 SMA-positive areas was  $41.8 \pm 24.3\%$ , and  $57.5 \pm 24.8\%$  in the  $\alpha$ -SMA-positive cells (E).  
572 Scale bar = 100  $\mu\text{m}$

573

574 Figure 5. Correlation between Sirius Red-positive collagen and myoglobin density.  
575 In the Sirius Red-stained image (top left), uniform Sirius Red-positive areas were selected  
576 (circled), and the percentage of the Sirius Red-positive area was calculated (45.0% in this  
577 example). The equivalent area on the myoglobin-stained fluorescence photograph (lower left)  
578 was selected and the percentage of the myoglobin-positive area was calculated (0.09% in this  
579 example). Spearman's rank correlation coefficient was analyzed by plotting data from 14  
580 regions of 12 samples. A correlation was found between the two densities ( $\rho = 0.593$ ,  $p =$   
581  $0.036$ ). Scale bar = 200  $\mu\text{m}$ .

582

583 Figure 6. The possible role of myoglobin in determining aneurysmal wall thickness.  
584 Hemodynamically, areas with high oscillations in wall shear stress vectors (high OSI,  
585 relatively low WSS) allow fibroblast differentiation into myofibroblasts. The myofibroblasts  
586 secrete myoglobin which inactivates NO and ROS, which in turn suppress MMP-2 and  
587 MMP-9, and reduce ECM degradation, resulting in relative wall thickening. In contrast,  
588 myoglobin is not produced in areas where the wall shear stress vector does not fluctuate (low  
589 OSI, relatively high WSS). In these areas, NO and ROS cause the activation of MMP-2 and  
590 MMP-9, leading to collagen fiber fragmentation and reduction, and resulting in wall thinning.  
591 AN wall, aneurysmal wall; ECM, extracellular matrix; Fb, fibroblast; Ma, macrophage; Mfb,  
592 myofibroblast; MMP-2,9, matrix metalloproteinase-2 and matrix metalloproteinase-9; Myo,  
593 myoglobin; NO, nitric oxide; OSI, oscillatory shear index; MMP, matrix metalloproteinase.

594

595 Supplementary Figure 1. Flowchart of sample selection for proteome and  
596 immunohistochemical analysis

597


598 Supplementary Figure 2. Accuracy of co-localization ratios between the cell counts and the  
599 areas

600 Receiver operating characteristic curves in differentiating co-localization ratios of  
601 myoglobin/periostin cell count from those of myoglobin/SMA cell count (solid line) and co-  
602 localization ratios of myoglobin/periostin area from those of myoglobin/SMA area (dashed  
603 line). The values of area under the curve (AUC) are not significantly different between the  
604 cell count and the area (0.975 [95% CI 0.937 – 1] versus 0.867 [95% CI 0.734 - 0.999]),  
605 respectively;  $p = 0.0525$ ).


606

607


A



B








C




D







A

 $\alpha$ -SMA

Myoglobin




Merge




B


Periostin



Myoglobin




Merge






C

Cell count





Area







**C** Merge ( $\alpha$ -SMA & Periostin)



**E** Periostin /  $\alpha$ -SMA ratio







## Correlation between collagen and Myoglobin density

